Kemin Industries, a global ingredient manufacturer focused on improving the quality of life for more than half the world’s population, has established a new partnership with CRVAB Bio-technology Co. Ltd., based in Chifeng, Inner Mongolia, China.
Since 1980, Kemin has been a global market leader in blending enzymes for feed. To further expand the global reach for Kemin in enzyme production, the investment will give Kemin fermentation and production capabilities. This will allow Kemin to directly control its production of enzymes, provide customers with higher-quality solutions and even greater consistency in enzyme products.
“With this investment, we will be able to better serve more customers in the global feed enzymes markets and will become basic in enzyme production,” said Dr. Chris Nelson, president and CEO of Kemin Industries. “As a company founded on science and innovation to improve lives around the world, we are always searching for ways to create impact and this new partnership allows us to expand into areas like food and textile applications.”
Kemin will have expanded resources for innovations in single and blended enzymes as well as probiotic product pipelines as Kemin works on a new product portfolio to bring enzyme products to market. The investment will give Kemin one of the most efficient fermentation facilities in China and an accelerated ability to bring products to Kemin customers.
“We are very excited to have Kemin as a trusted partner. This will significantly improve our capability and allow us to produce products meeting the highest international quality standards,” said Mr. Peijun Wu, Chairman of CRVAB Bio-technology Company Ltd.
“As the feed and animal production industry continues to evolve, customers are searching more aggressively for innovations that add real value,” said GS Ramesh, Kemin global group president, animal nutrition and health. “Kemin continues to be the key driver of product and technology innovations globally. This new partnership will further strengthen our capability to quickly scale up new innovations, while maintaining our quality and safety standards for global regulatory requirements.”